Who are Tezepelumab (APFS)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tezepelumab (Arm1&Arm2), Biological: Experimental: Tezepelumab, Experimental: Tezepelumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tezepelumab-apfs.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tezepelumab (APFS) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tezepelumab (APFS) (Tezepelumab (APFS)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-33/ST2 pathway inhibitor. Area: Immunology.

phase 3 IL-33/ST2 pathway inhibitor TSLP Immunology Biologic Live · refreshed every 30 min

Target snapshot

Tezepelumab (APFS) (Tezepelumab (APFS)) — AstraZeneca. Tezepelumab is a monoclonal antibody that targets and blocks the activity of thymic stromal lymphopoietin (TSLP), a cytokine involved in the initiation of allergic inflammation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tezepelumab (APFS) TARGET	Tezepelumab (APFS)	AstraZeneca	phase 3	IL-33/ST2 pathway inhibitor	TSLP
tezepelumab (Arm1&Arm2)	tezepelumab (Arm1&Arm2)	Qilu Pharmaceutical Co., Ltd.	phase 3	Monoclonal antibody	Thymic stromal lymphopoietin (TSLP)
Biological: Experimental: Tezepelumab	Biological: Experimental: Tezepelumab	AstraZeneca	phase 3	TSLP antagonist monoclonal antibody	TSLP (Thymic Stromal Lymphopoietin)
Experimental: Tezepelumab	Experimental: Tezepelumab	AstraZeneca	phase 3	Monoclonal antibody; TSLP inhibitor	TSLP (Thymic Stromal Lymphopoietin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-33/ST2 pathway inhibitor class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tezepelumab (APFS) — Competitive Intelligence Brief. https://druglandscape.com/ci/tezepelumab-apfs. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing